All News

Found 834 articles

• Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

  8/22/2022

  Cara Therapeutics, Inc. today announced data from the KOMFORT Phase 2 clinical trial evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica will be presented during a late-breaking news session at the 31st European Academy.

• Non-opioid Analgesics Market Size, Share, Growth, Forecast Report 2022 to 2030

  8/22/2022

  Non-opioid analgesics have broad applications in treating mild or severe pain, including pain associated with musculoskeletal, surgical, trauma, cancer, or other types of pain.

• Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

  8/19/2022

  Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products.

• 

  Jazz Takes Groundbreaking Epilepsy Drug into Kids in Phase III Trial

  8/18/2022

  Jazz Pharma is breaking new ground with its cannabidiol epilepsy treatment Epidiolex, taking the drug into a Phase III study in children and adolescents.

• ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/15/2022

  ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced financial results and business updates for the second quarter ended June 30, 2022.

• Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

  8/11/2022

  Homology Medicines, Inc., a genetic medicines company, announced the details of HMI-204, its optimized, in vivo, one-time gene therapy product candidate for the treatment of metachromatic leukodystrophy.

• Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

  8/9/2022

  Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

• Cara Therapeutics Reports Second Quarter 2022 Financial Results

  8/8/2022

  Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the second quarter ended June 30, 2022.

• Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

  8/1/2022

  Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report second quarter 2022 financial results and provide a corporate update.

• Pruritus Treatment Market Insights: Competitive Scenario of the Industry with Growth Prospect 2030

  7/25/2022

  Forecast to 2030,’ thoroughly examines the Pruritus Treatment industry to provide essential data & information for the targeted readers.

• Independent Clinical Studies Published Regarding Performance of Axumin® (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen Deprivation Therapy (ADT)

  7/19/2022

  Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today shared news of the publication of two independent, retrospective studies evaluating the use of Axumin® (fluciclovine F 18) PET imaging in men with biochemical recurrence of prostate cancer who were undergoing androgen deprivation therapy (ADT).

• Vir Biotechnology Announces Transition of Chief Scientific Officer

  7/14/2022

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Herbert “Skip” Virgin, M.D., Ph.D., Vir’s executive vice president, research and chief scientific officer, will step down effective August 31, 2022 to pursue a new position as chief medical officer and head of the Altos Institute of Medicine.

• Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

  7/5/2022

  AAVHSC16 Biodistribution Properties in Preclinical Models Demonstrated Potential for Systemic Delivery of Genetic Medicines to Brain, Heart and Muscle.

• Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU

  6/29/2022

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences: FASEB’s The Genome Engineering Conference: Cutting-Edge Research and Applications on June 29, 2022 at 5:30 p.m. WET/12:30 p.m. ET in Lisbon, Portugal.

• Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022

  6/22/2022

  Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), today announced that results from clinical trials of TERN-501, TERN-101 and TERN-201 will be highlighted in several presentations at the European Association for the Study of the Liver (EASL) International Liver Congress.

• Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU

  6/13/2022

  Homology Medicines, Inc., a genetic medicines company, announced that the U.S. Food and Drug Administration lifted the clinical hold previously placed on the pheNIX gene therapy clinical trial with investigational HMI-102 for adults with phenylketonuria.

• Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

  6/8/2022

  Terns Pharmaceuticals, Inc. announced that five abstracts detailing clinical data for multiple non-alcoholic steatohepatitis programs within the Company's portfolio were accepted for presentation at The International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom.

• Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022

  6/8/2022

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster presentations at the International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place in London and online June 22-26.

• Albireo to Present New Data at the EASL International Liver Congress™ 2022

  6/8/2022

  Albireo Pharma, Inc. today announced the presentation of seven abstracts/posters at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, being held June 22 – 26 in London.

• Amarin Appoints Tom Reilly as New Chief Financial Officer

  6/6/2022

  Amarin Corporation plc announced the appointment of Tom Reilly as Chief Financial Officer, effective June 20, 2022.